WallStreetZenWallStreetZen

NASDAQ: ACRV
Acrivon Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their ACRV stock forecasts and price targets.

Forecast return on equity

Is ACRV forecast to generate an efficient return?

Company
-58.13%
Industry
22.91%
Market
179.39%
ACRV's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ACRV forecast to generate an efficient return on assets?

Company
-50.84%
Industry
23.35%
ACRV is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ACRV earnings per share forecast

What is ACRV's earnings per share in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
-$1.89
Avg 2 year Forecast
-$1.62
Avg 3 year Forecast
-$1.35

ACRV revenue forecast

What is ACRV's revenue in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$11.3M

ACRV vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ACRV$1.73N/AN/A
PMN$8.34$47.80+473.14%Strong Buy
OKYO$1.40$5.00+257.14%Buy
CING$4.98$24.33+388.61%Strong Buy
CLLS$0.98$4.10+318.37%Hold
View Top Biotech Stocks

Acrivon Therapeutics Stock Forecast FAQ

What is ACRV's earnings growth forecast for 2026-2028?

(NASDAQ: ACRV) Acrivon Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.47%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.74%.

Acrivon Therapeutics's earnings in 2026 is -$74,225,000.On average, 9 Wall Street analysts forecast ACRV's earnings for 2026 to be -$80,864,294, with the lowest ACRV earnings forecast at -$85,252,478, and the highest ACRV earnings forecast at -$67,944,005. On average, 9 Wall Street analysts forecast ACRV's earnings for 2027 to be -$69,611,001, with the lowest ACRV earnings forecast at -$88,526,475, and the highest ACRV earnings forecast at -$38,246,626.

In 2028, ACRV is forecast to generate -$58,049,164 in earnings, with the lowest earnings forecast at -$96,591,478 and the highest earnings forecast at -$35,096,903.

If you're new to stock investing, here's how to buy Acrivon Therapeutics stock.

What is ACRV's revenue growth forecast for 2026-2028?

(NASDAQ: ACRV) Acrivon Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.16%.

Acrivon Therapeutics's revenue in 2026 is $0.On average, 9 Wall Street analysts forecast ACRV's revenue for 2026 to be $0, with the lowest ACRV revenue forecast at $0, and the highest ACRV revenue forecast at $0. On average, 9 Wall Street analysts forecast ACRV's revenue for 2027 to be $0, with the lowest ACRV revenue forecast at $0, and the highest ACRV revenue forecast at $0.

In 2028, ACRV is forecast to generate $482,314,589 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $1,570,361,450.

What is ACRV's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: ACRV) forecast ROA is -50.84%, which is lower than the forecast US Biotechnology industry average of 23.35%.

What is ACRV's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: ACRV) Acrivon Therapeutics's current Earnings Per Share (EPS) is -$1.88. On average, analysts forecast that ACRV's EPS will be -$1.89 for 2026, with the lowest EPS forecast at -$1.99, and the highest EPS forecast at -$1.59. On average, analysts forecast that ACRV's EPS will be -$1.62 for 2027, with the lowest EPS forecast at -$2.07, and the highest EPS forecast at -$0.89. In 2028, ACRV's EPS is forecast to hit -$1.35 (min: -$2.25, max: -$0.82).

What is ACRV's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: ACRV) forecast ROE is -58.13%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.